Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 3 Neoplasm Metastasis 2 Nasopharyngeal Carcinoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Peritoneal Neoplasms 1 Osteosarcoma 1 Liver, Cancer of, Primary Resectable 1 Hepatocellular Carcinoma Resectable 1 Head and Neck Neoplasms 1 Carcinoma, Hepatocellular 1 Advanced Gastric Cancer 1 Acute Toxic Effects 1

Interventions

Oxaliplatin 290 Capecitabine 206 Fluorouracil 181 Cisplatin 168 Docetaxel 138 S 1 (combination) 132 Paclitaxel 121 Leucovorin 116 Irinotecan 106 pembrolizumab 103 Trastuzumab 72 apatinib 56 Nivolumab 56 sintilimab 45 Drug Therapy 43 Surgical Procedures, Operative 37 Radiotherapy 37 Bevacizumab 37 Ramucirumab 34 titanium silicide 31 Hyperthermic Intraperitoneal Chemotherapy 30 Epirubicin 30 Carboplatin 30 tislelizumab 28 Cyclophosphamide 27 XELOX 24 Tegafur 23 Folfox protocol 22 Albumin-Bound Paclitaxel 22 camrelizumab 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Stomach Neoplasms × lobaplatin × Clear all

NCT04808466 2022-02-21

WUHIPEC01

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡